212 Pb TCMC trastuzumab

Drug Profile

212 Pb TCMC trastuzumab

Alternative Names: 212 Pb-trastuzumab

Latest Information Update: 22 Feb 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AREVA Med
  • Developer Orano Med; University of Alabama at Birmingham; University of Cincinnati
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer metastases; Prostate cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer-metastases in USA (Intraperitoneal, Infusion)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Prostate-cancer in USA (IV, Injection)
  • 01 Jul 2016 Areva completes a phase-I clinical trial in Cancer metastases in USA (Intraperitoneal) (NCT01384253)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top